China's Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017

Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion is possibly related to race and regions.  In China, the PH morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the relatively high morbidity among patients suffering from diseases in the nervous system, respiratory system and reproductive system. The morbidity of people with a family history of PH is over 50%. Only under severe symptoms will PH patients need the surgical treatment. In most cases, the long-term drug treatment is adopted. Currently, the common clinical drugs include receptor blocking agents, antiandrogen drugs, traditional Chinese medicine preparations, plant preparations, etc. 


Original Post Research Report on China's Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017

Source Researchmoz

 

SHARE

Milan Tomic

Hi. I’m Designer of Blog Magic. I’m CEO/Founder of ThemeXpose. I’m Creative Art Director, Web Designer, UI/UX Designer, Interaction Designer, Industrial Designer, Web Developer, Business Enthusiast, StartUp Enthusiast, Speaker, Writer and Photographer. Inspired to make things looks better.

  • Image
  • Image
  • Image
  • Image
  • Image
    Blogger Comment
    Facebook Comment

0 comments:

Post a Comment